Standout Papers

Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and ... 2013 2026 2017 2021 742
  1. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA) (2013)
    Andreas Schneeweiß, Stephen Chia et al. Annals of Oncology

Citation Impact

2 by Nobel laureates 6 from Science/Nature 64 standout
Sub-graph 1 of 19

Citing Papers

Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study
2023 Standout
Deciphering breast cancer: from biology to the clinic
2023 Standout
27 intermediate papers

Works of G. Ross being referenced

Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)
2013 Standout
Pertuzumab monotherapy following trastuzumab-based treatment: Activity and tolerability in patients with advanced HER2- positive breast cancer
2009
and 12 more

Author Peers

Author Oncology Molecular Biology PRM Cancer Research RNMI Last Decade Papers Cites
G. Ross 1324 306 284 552 528 48 1.8k
Jane E. Axon 2 20 20 1 5 11 271
Sheetal Dhar 8 86 6 3 3 10 491
A.J. Havinga 19 15 548
Washington Benítez‐Ortiz 5 29 1 1 3 39 559
Andrew J. Schwartz 13 1 114 15 395

All Works

Loading papers...

Rankless by CCL
2026